Integrating BNP and Novel Biomarkers Into Heart Failure Clinical Practice

What the researchers found

Practical framework for integrating natriuretic peptides and novel biomarkers into heart failure diagnosis and management, bridging research evidence to clinical implementation.

Why it matters

These findings are relevant to the growing population of patients using or considering peptide-based therapies.

The numbers in context

Review covers multiple emerging biomarkers and proposes practical thresholds and algorithms for clinical use.

How the study worked

Study design and methodology detailed in the full publication.

Who was studied

Patients with cardiorenal syndrome across reviewed studies

What this study cannot tell us

Study limitations discussed in the full publication.

How to read the evidence

Evidence assessment based on study design in publication.

When this study was published

Published in 2025.

The bigger picture

This study contributes to the expanding evidence for peptide-based therapeutics in clinical medicine.

Questions still open

• What are the long-term implications?
• How do results compare to existing evidence?
• What further research is needed?

Common questions

Read the original research

Integrating Novel Biomarkers into Clinical Practice: A Practical Framework for Diagnosis and Management of Cardiorenal Syndrome.

Life (Basel, Switzerland), 15(10)

Citation

Aletras, Georgios; Bachlitzanaki, Maria; Stratinaki, Maria; Lamprogiannakis, Emmanuel; Petrakis, Ioannis; Foukarakis, Emmanuel; Pantazis, Yannis; Hamilos, Michael; Stylianou, Kostas. (2025). Integrating Novel Biomarkers into Clinical Practice: A Practical Framework for Diagnosis and Management of Cardiorenal Syndrome.. Life (Basel, Switzerland), 15(10). https://doi.org/10.3390/life15101540